RAS mutant tumors have been largely refractory to therapies until now. Recent findings published in the New England Journal of Medicine show that sotorasib provides clinical benefit for KRAS p.G12C-mutated non-small-cell lung cancer (NSCLC) and provide mechanistic insights into acquired resistance to KRAS-specific inhibition.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ccell.2021.07.011 | DOI Listing |
Publication Analysis
Top Keywords
promise peril
4
peril kras
4
kras g12c
4
g12c inhibitors
4
inhibitors ras
4
ras mutant
4
mutant tumors
4
tumors refractory
4
refractory therapies
4
therapies findings
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!